Fig. 2From: Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patientsAdverse events following ide-cel administration. A Frequency and grade of presentation, B Median time to onset and duration of hematologic toxicity. Dashed lines show the upper limit of the median duration range. Abbreviations: CRS: cytokine release syndrome; DIC: disseminated intravascular coagulation; ICANS: immune effector cell-associated neurotoxicity syndromeBack to article page